DNTH
Price
$23.85
Change
+$0.28 (+1.19%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
758.68M
ERAS
Price
$1.60
Change
+$0.03 (+1.91%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
445.36M
64 days until earnings call
Interact to see
Advertisement

DNTH vs ERAS

Header iconDNTH vs ERAS Comparison
Open Charts DNTH vs ERASBanner chart's image
Dianthus Therapeutics
Price$23.85
Change+$0.28 (+1.19%)
Volume$1.31K
Capitalization758.68M
Erasca
Price$1.60
Change+$0.03 (+1.91%)
Volume$5.78K
Capitalization445.36M
DNTH vs ERAS Comparison Chart in %
Loading...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNTH vs. ERAS commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNTH is a Buy and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (DNTH: $23.57 vs. ERAS: $1.57)
Brand notoriety: DNTH and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNTH: 93% vs. ERAS: 69%
Market capitalization -- DNTH: $758.68M vs. ERAS: $445.36M
DNTH [@Biotechnology] is valued at $758.68M. ERAS’s [@Biotechnology] market capitalization is $445.36M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNTH’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • DNTH’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, DNTH is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNTH’s TA Score shows that 4 TA indicator(s) are bullish while ERAS’s TA Score has 5 bullish TA indicator(s).

  • DNTH’s TA Score: 4 bullish, 4 bearish.
  • ERAS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than DNTH.

Price Growth

DNTH (@Biotechnology) experienced а -3.00% price change this week, while ERAS (@Biotechnology) price change was -1.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.83%. For the same industry, the average monthly price growth was +22.37%, and the average quarterly price growth was +32.94%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+6.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNTH($759M) has a higher market cap than ERAS($445M). DNTH YTD gains are higher at: 8.119 vs. ERAS (-37.450). DNTH (-129.49M) and ERAS (-135.93M) have comparable annual earnings (EBITDA) . ERAS has more cash in the bank: 301M vs. DNTH (257M). DNTH has less debt than ERAS: DNTH (1.33M) vs ERAS (49.4M). DNTH has higher revenues than ERAS: DNTH (4.85M) vs ERAS (0).
DNTHERASDNTH / ERAS
Capitalization759M445M171%
EBITDA-129.49M-135.93M95%
Gain YTD8.119-37.450-22%
P/E Ratio3.24N/A-
Revenue4.85M0-
Total Cash257M301M85%
Total Debt1.33M49.4M3%
FUNDAMENTALS RATINGS
DNTH: Fundamental Ratings
DNTH
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
PROFIT vs RISK RATING
1..100
46
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
45
P/E GROWTH RATING
1..100
65
SEASONALITY SCORE
1..100
41

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DNTHERAS
RSI
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 7 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
83%
Momentum
ODDS (%)
Bullish Trend 5 days ago
84%
Bearish Trend 5 days ago
90%
MACD
ODDS (%)
Bullish Trend 5 days ago
85%
Bullish Trend 5 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 5 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
79%
Bullish Trend 5 days ago
78%
Advances
ODDS (%)
Bullish Trend 12 days ago
79%
Bullish Trend 12 days ago
80%
Declines
ODDS (%)
Bearish Trend 26 days ago
88%
Bearish Trend 6 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
89%
N/A
Aroon
ODDS (%)
N/A
Bullish Trend 5 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AFCHX17.15-0.08
-0.46%
American Century Focused Intl Gr C
BRXUX16.24-0.08
-0.49%
MFS Blended Research Intl Eq R4
MPLIX15.35-0.08
-0.52%
Praxis International Index I
SIECX12.69-0.10
-0.78%
Saratoga International Equity C
ODIIX134.85-2.07
-1.51%
Invesco Discovery R6

DNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with IMNM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
-5.00%
IMNM - DNTH
55%
Loosely correlated
-3.94%
XNCR - DNTH
50%
Loosely correlated
+0.99%
ERAS - DNTH
50%
Loosely correlated
N/A
CRNX - DNTH
50%
Loosely correlated
+1.11%
OCUL - DNTH
50%
Loosely correlated
-2.48%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with OCUL. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
N/A
OCUL - ERAS
53%
Loosely correlated
-2.48%
XNCR - ERAS
53%
Loosely correlated
+0.99%
RVMD - ERAS
53%
Loosely correlated
-0.93%
BEAM - ERAS
51%
Loosely correlated
-2.91%
IRON - ERAS
50%
Loosely correlated
-0.03%
More